Andrew J. Murphy, Co-Chief Scientific Officer at REGENERON PHARMACEUTICALS, INC. (REGN), sold 17,000 shares at $753.76 ($12.9M) on 2026-10-14, disclosed to the SEC on 2026-10-15.
Scheduled sale ($12.9M) by Co-Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $754.58 | 12,853 | $9.7M | 75.2% |
| 2 | $753.76 | 6 | $5K | 0.0% |
| 3 | $755.91 | 35 | $26K | 0.2% |
| 4 | $757.68 | 16 | $12K | 0.1% |
| 5 | $758.16 | 24 | $18K | 0.1% |
| 6 | $759.96 | 14 |
| $11K |
| 0.1% |
| 7 | $760.65 | 74 | $56K | 0.4% |
| 8 | $761.36 | 27 | $21K | 0.2% |
| 9 | $762.57 | 55 | $42K | 0.3% |
| 10 | $763.76 | 25 | $19K | 0.1% |
| 11 | $764.40 | 219 | $167K | 1.3% |
| 12 | $765.39 | 271 | $207K | 1.6% |
| 13 | $766.47 | 279 | $214K | 1.7% |
| 14 | $767.39 | 192 | $147K | 1.1% |
| 15 | $768.33 | 105 | $81K | 0.6% |
| 16 | $769.30 | 127 | $98K | 0.8% |
| 17 | $770.20 | 12 | $9K | 0.1% |
| 18 | $771.56 | 283 | $218K | 1.7% |
| 19 | $772.56 | 211 | $163K | 1.3% |
| 20 | $773.40 | 224 | $173K | 1.3% |
| 21 | $774.48 | 121 | $94K | 0.7% |
| 22 | $775.46 | 376 | $292K | 2.3% |
| 23 | $776.31 | 66 | $51K | 0.4% |
| 24 | $777.76 | 38 | $30K | 0.2% |
| 25 | $778.64 | 454 | $354K | 2.7% |
| 26 | $779.59 | 380 | $296K | 2.3% |
| 27 | $780.63 | 463 | $361K | 2.8% |
| 28 | $781.47 | 50 | $39K | 0.3% |
| Total | $759.00 avg | 17,000 | $12.9M | 100% |
| Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |
| REGN | SELL | 2022-11-16 | $5.2M | — | Filing → |